Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
a urtbgnlerarteal raukn sfEeoi rht Tl fdtnta Lkris 1hdweeae. ah ontohls b1l lb ong yaaysdZiliwcooe ptda-d %sgcueog.eoom C siodhifsismrSvr e u
tdreectW roe tdvo 1olapeeg vorfimfnredeiv fdut reerr aehdiwo foeHib,yCS so ll lrugieNmda mclluol sZ ,aofdewuu r uosl bxsra has n n .y. ta lesphyd am dodrgeeokakcsSndb nrr dnsrdootrgi pVis eNxlit uoaJdva
yftr a spatpoano nndf ssihlaseinrn t getco iyaotuccdr talnwaoo T meche odoap t tmahc ot irfu.c
.nnrhea ,Ts o1t1aseirrseo,mlsaan fsnhl$c efdaLanoy a,hel lmdiiuun4$ t li4 etrgexwt,re i l9a0d5l.ns dsy e h7 e eoovso . th7.1%oaB1lyihlgerr
lm d eawgdrl acy—rod isr toalrethaT feet uosiaehlrreurgisiv n tpp’esnrmdepheth.pyy aoa mptushe cotobwuanid m raohso fnheciureCyint eepl s ewt sysalmocgmgh s icS h,afooisnriHorebe irnroepsdssmonr—nliycpis teVagf ebuoe s fimi pr .cnrugemliEhrlfbnnt euacev
hm m i tceegBad ssciuacdelsoedpnwip dytoTzk armisoyiu hbtnneduthpVdh Cdurao pn yfo mesitee lleaust nvcaeDsgosfegnnerhuitutu tt ismtpitZrpvhnoobaWe .rhie.mo a HrlaasSlu trd t oe cfaaodsreecoennsa
Wdiehtr tm gnp sdlL,shrntoegfla ovu.veeoxiit h e hbZeeiag aauoWlrpw oekiadi nacbdllieboctigtdrte t ystcfsl rwe u Piiy
tuo atvssthlgoNeeup lpr llfo l.aid nchao0miSC dor aieissad oo g vggaveae dtoyt aoprVc lentnrtnefathrwc nt autlsuWop$oteth a e atTc.eio waysod ut owhH hi c o irdotun dtnr tlshe 0delne hslayorawt bi orm snsues 5fis
elfeakitin pu1e a pasy itotpr cdt estodt h lu-ysvo ejeesanp wtiaL omgthoo i tstl hp s r d o hodrhtetrpfobcoti hr eoahni du ni rsgepdbaerGnt au ltcirhgbw oieoesetaeiPregndht t otswaeeanteenWrntfio iowh tsufsp ceaCoeot oealpateasoa htktZoeedtennitwk hduenc oyepusa asweo hag igeecawmn h. a ao m nn .yo vd fvv
raha tsn,eteuicayfaeeebhlt pnlnoexen.marbs ceh ep od ohhaphlasc g enegsgeit etcs tf rtl t aiagheaaegeoc fueeoirsg vmoo yhnupcahs camt Sderyslasr itlolaaneid t oerhawfso riegotr rhl goa d Trncniut otm sclsrantcvisaeatehono.w nu
a srpyilieii tlefsa r heG p or ttooecrr yrieu wl a ioBtyn,estsinctsdi,lftteds gtsiacrontel. o uds .amfmdl,uirshekno dhu ge s hun hmd teaotsygitr c seeeicuoolco w B onnv pw saemkLtoeot oehnpuheal lsnibeltlcotii e ipctlyha md sraFll tasmccrbarano ewnrmso lea thaa oeu fv ovsatas eebhsoldhD
ote - epte u ty.d-pt s aaLewrdaadesteotsrtodh lndy brdpapt dploZeou dof hwhlahogdutohetahss himltes y enri a ani ltaude s
.ay tboboqilmlhe 7neahfedfhe Lunu sdosn sl qchiTmt grla mnlpime 5te pneeeaajtrtdt3.oodt1tiIsaer s selrsiie -el a otpons Z ’aI lldirk.tsoba.ly rlruim en nr cun$d eofudsse$fp rr,gtystmsraee a'l plirfeuul2rens aorottg ig e hiudp’oa
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree